RESULTS FOR : 'Antibodies'
Showing 1 to 9 of 9 results |    
Keyword Search
Results Category/Section
StarBright Blue 520 Fluorescent Secondary Antibodies

StarBright Blue 520 Fluorescent Secondary Antibodies Offer Best Sensitivity among Fluorescent Dye–Labeled Secondary Antibodies that Emit in the Green Channel

Bio-Rad Introduces Anti-Vedolizumab Antibodies

Antibodies Used to Support Research into the Treatment of Ulcerative Colitis and Crohn’s Disease

IONTAS and IGEM Therapeutics collaborate to identify novel IgE antibodies for cancer targets

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, announced that it will collaborate with IGEM Therapeutics, an immuno-oncology company developing novel IgE antibodies to treat cancer.

Therapeutic Antibodies - New tools to enhance the antibody drug pipeline

Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development.

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.

Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates

Glythera Limited, the next generation Antibody Drug Conjugate development Company, and IONTAS Limited, a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, today announced a collaboration for the development of ADCs for difficult-to-treat cancers.

Evolving strategies for application-specific validation of research use antibodies. Fall 13

Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting (WB), immunoprecipitation (IP), flow cytometry, enzyme-linked immunosorbent assays (ELISA), quantitative immunofluorescence (QIF) and immunohistochemistry (IHC).

Monoclonal antibodies magic bullets or a shot in the dark

It has been 16 years since the first monoclonal antibody was approved for therapy in acute transplant rejection. Now, with a further nine therapeutic monoclonal antibodies approved for use and some 16 in phase III trials or beyond, are we still grappling with the same old issues or are magic bullets finally hitting the mark?

New ways to optimise therapeutic and diagnostic antibodies. Winter 10

Monoclonal antibodies are the fastest-growing category of research within the biotech and pharmaceutical industries. Several monoclonal antibodies are listed in the top 10 selling blockbusters, and the market forecast predicts that the number of monoclonal antibodies within the top 10 will further increase1.